Recent $19M Funding Round

Amount: $19 million (approximately £14.2 million / €16.6 million) .

Date announced: July 24, 2026 .

Round: Series C .

Lead investor: Cross-Border Impact Ventures .

Participating investors: Returning backers BGF, Airstream Capital, Foresight Group, and Downing .

Total funding to date: Specific cumulative figures are not publicly broken down in a single source, but the company has raised at least this Series C plus prior rounds from BGF, Airstream Capital, and Foresight Group . The device is already CE-marked and deployed in NHS regions in England prior to this raise .

Key UK COPD Statistics

• Diagnosed cases: Approximately 1.4 million people in the UK have a diagnosed COPD .
• Undiagnosed estimate: The true number is thought to be much higher; around 3.2 million adults may have COPD, with up to 2.1 million people (roughly 70%) undiagnosed .
• Prevalence: COPD affects about 2% of the total UK population and 4.5% of people over 40 . More broadly, studies estimate COPD prevalence between 3% and 6% of the population .
• Mortality: Around 30,000 people per year in the UK die from COPD , making it the second most common lung disease after asthma .
• Hospital admissions: In England in the financial year ending 2025, there were 118,975 emergency admissions for COPD (rate of 201 per 100,000 population) .

Rollout Plans

TidalSense plans to use the Series C funding for three main expansion tracks :

1. Expand across Europe – Commercialise and scale N-Tidal Diagnose in additional European markets.
2. Enter the U.S. market – Pursue regulatory clearance (FDA) and launch in the United States.
3. Scale within the NHS – Broaden deployment across more NHS regions in England beyond current early-adopter sites, and explore use in primary care to help close the diagnosis gap .

CEO Background

Dr Ameera Patel, MD PhD, is the Chief Executive Officer . She is an asthma patient herself, which gave her first-hand experience of the challenges of living with a long-term respiratory condition . Her personal difficulty in getting her own asthma diagnosed motivated her to build a better diagnostic approach. She holds both an MD and a PhD and leads the company from its Cambridge, UK headquarters .

Recent $19M Funding Round

Amount: $19 million (approximately £14.2 million / €16.6 million) .

Date announced: July 24, 2026 .

Round: Series C .

Lead investor: Cross-Border Impact Ventures .

Participating investors: Returning backers BGF, Airstream Capital, Foresight Group, and Downing .

Total funding to date: Specific cumulative figures are not publicly broken down in a single source, but the company has raised at least this Series C plus prior rounds from BGF, Airstream Capital, and Foresight Group . The device is already CE-marked and deployed in NHS regions in England prior to this raise .

Key UK COPD Statistics

• Diagnosed cases: Approximately 1.4 million people in the UK have a diagnosed COPD .
• Undiagnosed estimate: The true number is thought to be much higher; around 3.2 million adults may have COPD, with up to 2.1 million people (roughly 70%) undiagnosed .
• Prevalence: COPD affects about 2% of the total UK population and 4.5% of people over 40 . More broadly, studies estimate COPD prevalence between 3% and 6% of the population .
• Mortality: Around 30,000 people per year in the UK die from COPD , making it the second most common lung disease after asthma .
• Hospital admissions: In England in the financial year ending 2025, there were 118,975 emergency admissions for COPD (rate of 201 per 100,000 population) .

Rollout Plans

TidalSense plans to use the Series C funding for three main expansion tracks :

1. Expand across Europe – Commercialise and scale N-Tidal Diagnose in additional European markets.
2. Enter the U.S. market – Pursue regulatory clearance (FDA) and launch in the United States.
3. Scale within the NHS – Broaden deployment across more NHS regions in England beyond current early-adopter sites, and explore use in primary care to help close the diagnosis gap .

CEO Background

Dr Ameera Patel, MD PhD, is the Chief Executive Officer . She is an asthma patient herself, which gave her first-hand experience of the challenges of living with a long-term respiratory condition . Her personal difficulty in getting her own asthma diagnosed motivated her to build a better diagnostic approach. She holds both an MD and a PhD and leads the company from its Cambridge, UK headquarters .